The Regulatory Roles of Ezh2 in Response to Lipopolysaccharide (LPS) in Macrophages and Mice with Conditional Ezh2 Deletion with LysM-Cre System

被引:6
|
作者
Kunanopparat, Areerat [1 ,2 ]
Leelahavanichkul, Asada [2 ,3 ,4 ]
Visitchanakun, Peerapat [2 ]
Kueanjinda, Patipark [2 ]
Phuengmaung, Pornpimol [2 ]
Sae-khow, Kritsanawan [2 ]
Boonmee, Atsadang [1 ,5 ]
Benjaskulluecha, Salisa [1 ,5 ]
Palaga, Tanapat [1 ,5 ]
Hirankarn, Nattiya [1 ,2 ]
机构
[1] Chulalongkorn Univ, Ctr Excellence Immunol & Immune Mediated Dis, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Fac Med, Dept Microbiol, Bangkok 10330, Thailand
[3] Chulalongkorn Univ, Fac Med, Ctr Excellence Translat Res Inflammat & Immunol CE, Bangkok 10330, Thailand
[4] Chulalongkorn Univ, Fac Med, Dept Med, Div Nephrol, Bangkok 10330, Thailand
[5] Chulalongkorn Univ, Fac Sci, Dept Microbiol, Bangkok 10330, Thailand
关键词
sepsis; lipopolysaccharide; macrophages; epigenetics; Ezh2; NECROSIS-FACTOR-ALPHA; ACUTE KIDNEY INJURY; ENDOTOXIN TOLERANCE; CYTOKINE SIGNALING-3; IMMUNE DYSFUNCTION; T-CELLS; INTERLEUKIN-10; SEPSIS; EXPRESSION; INFLAMMATION;
D O I
10.3390/ijms24065363
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The responses of macrophages to lipopolysaccharide (LPS) might determine the direction of clinical manifestations of sepsis, which is the immune response against severe infection. Meanwhile, the enhancer of zeste homologue 2 (Ezh2), a histone lysine methyltransferase of epigenetic regulation, might interfere with LPS response. Transcriptomic analysis on LPS-activated wild-type macrophages demonstrated an alteration of several epigenetic enzymes. Although the Ezh2-silencing macrophages (RAW264.7), using small interfering RNA (siRNA), indicated a non-different response to the control cells after a single LPS stimulation, the Ezh2-reducing cells demonstrated a less severe LPS tolerance, after two LPS stimulations, as determined by the higher supernatant TNF-alpha. With a single LPS stimulation, Ezh2 null (Ezh2(flox/flox); LysM-Cre(cre/-)) macrophages demonstrated lower supernatant TNF-alpha than Ezh2 control (Ezh2(fl/fl); LysM-Cre(-/-)), perhaps due to an upregulation of Socs3, which is a suppressor of cytokine signaling 3, due to the loss of the Ezh2 gene. In LPS tolerance, Ezh2 null macrophages indicated higher supernatant TNF-alpha and IL-6 than the control, supporting an impact of the loss of the Ezh2 inhibitory gene. In parallel, Ezh2 null mice demonstrated lower serum TNF-alpha and IL-6 than the control mice after an LPS injection, indicating a less severe LPS-induced hyper-inflammation in Ezh2 null mice. On the other hand, there were similar serum cytokines after LPS tolerance and the non-reduction of serum cytokines after the second dose of LPS, indicating less severe LPS tolerance in Ezh2 null mice compared with control mice. In conclusion, an absence of Ezh2 in macrophages resulted in less severe LPS-induced inflammation, as indicated by low serum cytokines, with less severe LPS tolerance, as demonstrated by higher cytokine production, partly through the upregulated Socs3.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Destabilization of B2 RNA by EZH2 Activates the Stress Response
    Zovoilis, Athanasios
    Cifuentes-Rojas, Catherine
    Chu, Hsueh-Ping
    Hernandez, Alfredo J.
    Lee, Jeannie T.
    CELL, 2016, 167 (07) : 1788 - +
  • [32] Ezh2 mediates epigenetic regulation of osteoclastogenesis and bone remodeling in mice
    Chen, Jin-Ran
    Lazarenko, Oxana
    Gai, Dongzheng
    Li, Can
    Blackburn, Michael
    Zhan, Fenghuang
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 213 - 213
  • [33] Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
    Kim, Jung
    Lee, Yongik
    Lu, Xiaodong
    Song, Bing
    Fong, Ka-Wing
    Cao, Qi
    Licht, Jonathan D.
    Zhao, Jonathan C.
    Yu, Jindan
    CELL REPORTS, 2018, 25 (10): : 2808 - +
  • [34] A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2
    Martijn A. J. Koppens
    Ellen Tanger
    Karim Nacerddine
    Bart Westerman
    Ji-Ying Song
    Maarten van Lohuizen
    Transgenic Research, 2017, 26 : 187 - 196
  • [35] Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model
    Caviness, Perry C.
    Gai, Dongzheng
    Lazarenko, Oxana P.
    Blackburn, Michael L.
    Zhan, Fenghuang
    Chen, Jin-Ran
    FASEB JOURNAL, 2023, 37 (07): : e23019
  • [36] A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2
    Koppens, Martijn A. J.
    Tanger, Ellen
    Nacerddine, Karim
    Westerman, Bart
    Song, Ji-Ying
    van Lohuizen, Maarten
    TRANSGENIC RESEARCH, 2017, 26 (02) : 187 - 196
  • [37] Critical Roles Of Enhancer Of Zeste Homolog 2(ezh2) During Influenza A Virus Infection
    Yagi, K.
    Ishii, M.
    Namkoong, H.
    Asami, T.
    Fujiwara, H.
    Nishimura, T.
    Saito, F.
    Tasaka, S.
    Kunke, S., I
    Hasegawa, N.
    Betsuyakul, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [38] The histone methyltransferase EZH2 is required for normal uterine development and function in mice
    Nanjappa, Manjunatha K.
    Mesa, Ana M.
    Medrano, Theresa I.
    Jefferson, Wendy N.
    DeMayo, Francesco J.
    Williams, Carmen J.
    Lydon, John P.
    Levin, Ellis R.
    Cooke, Paul S.
    BIOLOGY OF REPRODUCTION, 2019, 101 (02) : 306 - 317
  • [39] VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2-Targeted Therapy
    Riquelme, Erick
    Suraokar, Milind
    Behrens, Carmen
    Lin, Heather Y.
    Girard, Luc
    Nilsson, Monique B.
    Simon, George
    Wang, Jing
    Coombes, Kevin R.
    Lee, J. Jack
    Hong, Waun Ki
    Heymach, John
    Minna, John D.
    Wistuba, Ignacio I.
    CLINICAL CANCER RESEARCH, 2014, 20 (14) : 3849 - 3861
  • [40] Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic
    Guo, Yunyun
    Cheng, Rui
    Wang, Yuqing
    Gonzalez, Maria E.
    Zhang, Hongshan
    Liu, Yang
    Kleer, Celina G.
    Xue, Lixiang
    EBIOMEDICINE, 2024, 100